PXL065 proves safe, well-tolerated ahead of phase 2 trial for NASH

Poxel announced positive safety, tolerability and pharmacokinetic results from a phase 1b multiple ascending dose trial of PXL065, a deuterium-stabilized R-stereoisomer of Actos under investigation for nonalcoholic steatohepatitis, according to a press release.
“NASH is a major public health concern and is a growing contributor to the burden of end-stage liver disease. There remains an urgent need to develop effective therapeutics for NASH,” Arun Sanyal, MD, from the Virginia Commonwealth University School of Medicine, said in the release. “[Actos] has been shown in multiple

Source link

Related posts

Study finds negligible gluten transfer when children use Play Doh, uncooked pasta for play


Adhesive small bowel obstruction surgery reduces recurrence risk


Simulated microgravity promotes the formation of tridimensional cultures and stimulates pluripotency and a glycolytic metabolism in human hepatic and biliary tree stem/progenitor cells


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy